Standard BioTools Q3 core revenue up 30% sequentially to $24.8M; GAAP net loss $29.4M

STANDARD BIOTOOLS INC.

2022-Q3 EPS reported -$2.17 revenue$70,927,000

Core product/services revenue $24.8M, +30% sequentially; total revenue $25.6M, down from $28.5M YoY.
GAAP net loss $29.4M vs $13.8M in Q3 2021; non-GAAP net loss $20.8M vs $5.4M.
Cash, equivalents & short-term investments $185.2M at Sept 30, down from $211.2M at June 30.
First restructuring phase saves $8M annually; reiterates 65-68% non-GAAP gross margin goal by end of 2023.
Aiming for positive free cash flow by year-end 2024; launched X9 Real-Time PCR System.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

STANDARD BIOTOOLS INC. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Standard BioTools Inc. (the “Company”) issued a press release reporting its financial results for the third fiscal quarter of 2022.

View on SEC.gov

Browse all earnings releases →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0001171843-22-007235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.